GlassScriptPhysician profile
Rodney P Rocconi
NPI 1730131210
$223,870.47
in general payments reported to CMS, 2019-2025
27 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 75% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $15K · 2021: $50K · 2022: $84K · 2023: $32K · 2024: $12K · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,150 · Consulting Fee: $6,473 · Food and Beverage: $2,495 · Travel and Lodging: $2,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,154.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,150.00 |
| Consulting Fee | $6,472.50 |
| Food and Beverage | $2,495.20 |
| Travel and Lodging | $2,113.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $119,274.20 | 2020-2024 | Zejula, Jemperli |
| Eisai INC. | $40,033.48 | 2022-2024 | |
| Genentech USA, INC. | $21,483.76 | 2019 | |
| Clovis Oncology, INC. | $18,998.55 | 2019-2020 | |
| Roche Diagnostics Corporation | $8,180.00 | 2021 | |
| Immunogen, INC. | $6,724.18 | 2023 | Elahere |
| Intuitive Surgical, INC. | $4,167.76 | 2022 | |
| Abbvie INC. | $2,337.51 | 2019-2024 | |
| Histosonics, INC. | $1,284.88 | 2025 | |
| Baxter Healthcare | $261.29 | 2023-2024 | Floseal, Tisseel, Perclot |
| Seagen INC. | $153.93 | 2022 | |
| Medical Device Business Services, INC. | $149.03 | 2025 | Harmonic |
| Dilon Technologies, INC. | $142.12 | 2024 | Hemoblast Bellows |
| Biom'Up Sa | $116.22 | 2019 | |
| Merck Sharp & Dohme LLC | $110.53 | 2019-2023 | Keytruda, Lynparza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $95.04 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $92.44 | 2024 | Tivdak |
| Ethicon US, LLC | $79.69 | 2022-2025 | Dermabond |
| Astrazeneca Pharmaceuticals LP | $78.66 | 2022-2023 | Lynparza |
| Regeneron Healthcare Solutions, INC. | $25.34 | 2023 | Libtayo |
| Genentech, INC. | $23.65 | 2024 | Tecentriq Hybreza, Alecensa, Columvi |
| Novartis Pharmaceuticals Corporation | $21.93 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.19 | 2023 | Ultomiris |
| Janssen Biotech, INC. | $15.09 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Rocconi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.